STAT+: Pharmalittle: We’re reading about a pancreatic cancer drug approval, a Trump deal with biotechs, and more
The FDA approved a life-extending treatment for advanced pancreatic cancer from Revolution Medicines that is the first to attack a genetic cause
Good morning, everyone. We are doing well despite the weather. Today, we have some exciting news to share. The U.S. Food and Drug Administration has approved a new treatment for advanced pancreatic cancer. This life-extending therapy targets a genetic cause of the aggressive cancer, making it the first of its kind. A clinical trial demonstrated that patients receiving this drug as a second-line treatment had a significantly longer overall survival time compared to those given standard chemotherapy.
The Trump administration is also planning to announce new drug-pricing agreements with several mid-sized biotech companies on Monday. These agreements will involve providing discounts on outpatient drugs to state Medicaid programs, aligning prices with what the companies charge in foreign countries. However, participation by state Medicaid programs is optional, and the companies will not face pilot programs forcing similar discounts in Medicare. Some discussions may also involve relief from tariffs. For more details, continue to STAT+.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
